Coegin Pharma signs development agreement with a cosmetics company

Coegin Pharma has signed a Joint Development Agreement (JDA) with a cosmetics company already marketing several consumer brands. The purpose of the JDA is to jointly progress with the next phase of R&D activities for the unique skin pigmentation peptide NPP-4. This agreement lays the foundation for a potential commercialisation agreement in the future.

The JDA outlines that Coegin Pharma will provide the necessary NPP-4 testing materials for the upcoming phase of R&D activities, while the development partner will take care of the evaluation of NPP-4. This collaboration is a key step towards a potential licensing agreement for NPP-4, contingent upon positive results from the R&D activities and successful negotiations of commercial terms.

"We are very pleased having this JDA in place with a strong partner. This also allows us to maintain our focus on the commercialisation of our hair growth project, FOL005," says Jens Eriksson, CEO of Coegin Pharma.

For further information, please contact:
Jens Eriksson, CEO
Email: [email protected]
Phone: +46 72 221 24 21 

This information is information that Coegin Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 08:20 CET on 12 September 2024.

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia. Coegin is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026. 

Coegin Pharma's shares are listed on NGM Nordic SME and Börse Stuttgart, and the company have a registered office in Lund, Sweden. 

For more information, please visit: coeginpharma.com/en